Related Experiment Videos
Saquinavir/Ritonavir: its evolution and current treatment role
1AIDS Pathogenesis Research Program, Division of Infectious Diseases, University of Texas Medical Branch, Galveston, USA.
The AIDS Reader
|January 26, 2006
Summary
New HIV drug formulations, like boosted saquinavir mesylate, reduce pill burden for patients. This review covers clinical trials and benefits of these improved protease inhibitor regimens for effective viral control.
Area of Science:
- Pharmacology
- Virology
- Infectious Diseases
Background:
- HIV treatment has advanced with improved drug formulations and combinations.
- Physicians can now offer therapies that reduce pill burden while maintaining safety and viral control.
- Saquinavir mesylate, a protease inhibitor (PI), was reformulated to decrease pill burden.
Purpose of the Study:
- To review ritonavir-enhanced (boosted) saquinavir regimens.
- To discuss clinical trials evaluating this PI combination.
- To explore advantages and opportunities of using boosted saquinavir.
Main Methods:
- Literature review of clinical trials.
- Analysis of safety and efficacy data for boosted saquinavir regimens.
- Discussion of pharmacokinetic and pharmacodynamic principles of ritonavir boosting.
Main Results:
- Boosted saquinavir regimens demonstrate effective viral suppression.
- Reduced pill burden improves patient adherence and quality of life.
- Ritonavir boosting enhances saquinavir exposure and antiviral activity.
Conclusions:
- Boosted saquinavir mesylate offers a valuable option for HIV management.
- Optimized drug formulations contribute to better patient outcomes in HIV therapy.
- Further research can explore expanded use of boosted PI regimens.